



Nationwide Incidence Rate

1 in 9 men will be diagnosed during his lifetime
2.9M men currently diagnosed

This year in the United States...

New cases: 174,650
Deaths: 31,620

Veterans are 1.5x more likely to get prostate cancer

African-American men are 2.2x more likely to die of prostate cancer

Incidence Rate in Maryland

125.7 in every 100,000 men diagnosed
20.2 in every 100,000 men die from the disease

This year in Maryland...

New cases: 3,810
Deaths: 550

National Rankings by State:

#8 for prostate cancer incidents
#16 for prostate cancer deaths

Source: Estimates based on 2019 data from the American Cancer Society.

ZERO's Impact in Maryland

Patient Programs

ZERO helped provide co-pay assistance to advanced prostate cancer patients:

\$2,480,455.14 total provided to
604 men in Maryland.

Upcoming Invitations to Speak to Constituents

Baltimore – September 22

ZERO – The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. Visit our website: www.zerocancer.org.

ZERO Contact:

Matt Marks
Government Relations & Advocacy Manager
matt@zerocancer.org | 202-664-4342



CDMRP Grants in Maryland

Year introduced: 1997

Total Grants to Date: 188

Total Grant Awards to through FY 2017*: \$92.1M

**PCRP data for FY 2018 has not been posted yet*

Grant Recipient	Year	Amount
John Hopkins University	2013	\$6,055,088.00
John Hopkins University	2009	\$2,590,809.32
John Hopkins University	2013	\$2,022,501.00
John Hopkins University	2014	\$1,699,782.00
National Cancer Institute	2017	\$1,461,572.00

CDC's National Comprehensive Cancer Control Program (NCCCP) funding in Maryland:

- Goal 1: Reduce the burden of cancer in Maryland.
- Objective 1: By 2020, reduce age-adjusted cancer incidence rates to reach the following targets:
Prostate: 87.3 per 100,000 (2012 Baseline: 112.0 per 100,000).
- Objective 2: By 2020, reduce age-adjusted cancer mortality rates to reach the following targets:
Prostate: 11.2 per 100,000 (2012 Baseline: 20.4 per 100,000).
- Objective 3: By 2020, increase the proportion of men ages 55 to 69 who have discussed the advantages and disadvantages of the prostate-specific antigen (PSA) test to screen for prostate cancer with their healthcare provider to 38.2% of Maryland men ages 55 to 69 (2012 Baseline: 34.7% of Maryland men ages 55 to 69). Target Setting Method: 10% Increase.
- Objective 4: By 2020, reduce disparities in cancer incidence and mortality to reach the following targets:
Prostate Incidence: White: 68.7 per 100,000 (2012 baseline: 97.5 per 100,000), Black: 130.9 per 100,000 (2012 baseline: 159.7 per 100,000). Prostate mortality: White: 10.0 per 100,000 (2012 baseline: 17.4 per 100,000), Black: 13.5 per 100,000 (2012 baseline: 35.5 per 100,000).

ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. Visit our website: www.zerocancer.org.

ZERO Contact:

Matt Marks

Government Relations & Advocacy Manager

matt@zerocancer.org | 202-664-4342

